Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ) has shared an announcement.
Suzhou Basecare Medical Corporation Limited has obtained National Medical Products Administration approval in China for its independently developed Gems cleavage embryo culture medium as a Class III medical device. The product had already secured CE, U.S. FDA and Australian TGA certifications, reflecting its established international regulatory standing.
Developed using three decades of technological expertise from the Sydney IVF Center and more than a decade of overseas clinical validation, the upgraded medium is designed to improve early embryo stress resistance and developmental support for assisted reproduction in China. With this approval, all four core primary culture products in the Gems series are now fully certified, completing a sequential culture media portfolio and creating a closed-loop full-cycle embryo culture system that broadens clinical options for fertility specialists.
More about Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corporation Limited is a China-based medical device company focused on assisted reproductive technologies and embryo culture solutions. Its product portfolio includes the Gems series of embryo culture media, targeting fertility clinics and reproductive medicine centers in China and internationally.
Average Trading Volume: 108,127
Technical Sentiment Signal: Sell
Current Market Cap: HK$506M
Learn more about 2170 stock on TipRanks’ Stock Analysis page.